ADXN
Addex Therapeutics Ltd
NasdaqCM Healthcare Switzerland
2,99 $US
-1.97% today
-63.04% YTD · -65.63% 1Y
7
Insider transactions
SEC Form 4 · AMF · BaFin — rolling 90 days
0
Hedge funds tracked
Latest available SEC 13F filings
38
/ 100
WEAK

Analysis Addex Therapeutics Ltd (ADXN) — Kairos Score 38/100

Composite score aggregating 8 smart money dimensions: insiders (SEC/AMF/BaFin), hedge funds, politicians & gurus, price momentum, valuation, analyst consensus, financial health, earnings momentum. The higher the score, the more favorable the institutional signals consensus.

💡 Detailed breakdown (the 8 sub-scores) available in the Premium dashboard.

About Addex Therapeutics Ltd

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Key info

👔
CEO
Mr. Timothy Mark Dyer
📍
HQ
Chemin des Mines, 9, Geneva, 1202, Switzerland
👥
Employees
3
💰
Market cap
5 239 780,00 $US
💸
Dividend yield
0.00%

🕴️ Insider activity (90 days)

7 transactions — 0 buys and 0 sales reported by Addex Therapeutics Ltd executives.

KM
Kalinichev Mikhail
HEAD OF TRANSLATIONAL SCIENCE · 2026-09-02
Other
NJ
Nunn Jason Raleigh
2026-09-02
Other
MR
Mills Roger
CHIEF MEDICAL OFFICER · 2026-09-02
Other

🏦 Hedge Funds

0 institutional funds report a position on ADXN in their latest SEC quarterly filing.

📰 Recent news

15 recent articles on ADXN.

🧠 What makes Kairos Insider

Beyond raw data, we aggregate and score every smart money signal to give you a unique view.

🧠

Kairos Score 0-100

8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.

🎯

Insider Clusters

Detection of clustered purchases or sales by several executives in the same stock.

🏦

13F Hedge Funds

Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.

📈

ETF Rotations

NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.

🔥

Google Trends

Spot marked changes in search interest around the stocks being followed.

📧

Email alerts

Create your watchlist and receive a brief of events affecting your tickers.

Companies in the same sector as Addex Therapeutics Ltd

Official sources · Public data · SEC EDGAR — Form 4 & 13F · AMF — Executive filings · BaFin — Directors' Dealings · Yahoo Finance · Alpha Vantage

🔓 Unlock the full analysis

This public page only shows a preview. The full analysis of ADXN on the Kairos Insider dashboard includes:

✅ Full Kairos Score (8-axis radar + synthesis)
✅ History of all 7 insider transactions over 90 days
✅ All 0 detected institutional funds
✅ Thematic ETFs (ARK, BUZZ, NANC, GOP, JEPI…)
✅ Hot Stocks Google Trends
✅ Available history: AUM + rotations
✅ Fundamentals (P/E, PEG, EV/EBITDA, ROE…)
✅ Financial health (Altman Z, Piotroski F)
✅ Sector peers + recent earnings
See full analysis →
Analyze other tickers for free →

Free signup · Pro €19/month or €190/year